Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
Nuvectis Pharma Q3 Earnings Call Highlights
Nuvectis (NVCT) Q3 2026 Earnings Call Transcript
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma Q3 2026 Earnings Call Transcript
Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis Pharma Reports Data From Its Phase 1b Trial Of NXP200 Demonstrates Objective Response Rate Based On Response Assessment In Neuro-Oncology Criteria 2.0 Of 40%; Deep Responses Were 87.5%
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating
Nuvectis Pharma Files Base Prospectus Related To The Offer And Sale Of Up To $200M Of Securities
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.